Agenda - Challenges in drug development, regulation and clinical practice in immune thrombocytopenia

EMA/HMA European platform for regulatory science research platform meeting – draft agenda

Appendix 1: Acceptable intakes established for N-nitrosamines

Agenda of the PRAC meeting 8-11 June 2026

EMEA-001563-PIP02-15-M01

Human medicines European public assessment report (EPAR): Omjjara, momelotinib, Date of authorisation: 25/01/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Yescarta, axicabtagene ciloleucel, Date of authorisation: 23/08/2018, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Alecensa, alectinib, Date of authorisation: 16/02/2017, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Vyjuvek, beremagene geperpavec, Date of authorisation: 23/04/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 53, Status: Authorised